BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Matsuyama R, Morioka D, Mori R, Yabushita Y, Hiratani S, Ota Y, Kumamoto T, Endo I. Our Rationale of Initiating Neoadjuvant Chemotherapy for Hilar Cholangiocarcinoma: A Proposal of Criteria for "Borderline Resectable" in the Field of Surgery for Hilar Cholangiocarcinoma. World J Surg 2019;43:1094-104. [PMID: 30536024 DOI: 10.1007/s00268-018-04883-y] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
Number Citing Articles
1 Noji T, Nagayama M, Imai K, Kawamoto Y, Kuwatani M, Imamura M, Okamura K, Kimura Y, Hirano S. Conversion surgery for initially unresectable biliary malignancies: a multicenter retrospective cohort study. Surg Today 2020;50:1409-17. [PMID: 32468112 DOI: 10.1007/s00595-020-02031-5] [Reference Citation Analysis]
2 Kuriyama N, Usui M, Gyoten K, Hayasaki A, Fujii T, Iizawa Y, Kato H, Murata Y, Tanemura A, Kishiwada M, Sakurai H, Mizuno S, Isaji S. Neoadjuvant chemotherapy followed by curative-intent surgery for perihilar cholangiocarcinoma based on its anatomical resectability classification and lymph node status. BMC Cancer 2020;20:405. [PMID: 32393197 DOI: 10.1186/s12885-020-06895-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
3 Park HJ, Han DH, Choi GH, Choi JS. Surgical outcomes of perihilar cholangiocarcinoma based on the learning curve of a single surgeon at a tertiary academic hospital: A retrospective study. Ann Hepatobiliary Pancreat Surg 2021;25:54-61. [PMID: 33649255 DOI: 10.14701/ahbps.2021.25.1.54] [Reference Citation Analysis]
4 Jansson H, Cornillet M, Björkström NK, Sturesson C, Sparrelid E. Prognostic value of preoperative inflammatory markers in resectable biliary tract cancer - Validation and comparison of the Glasgow Prognostic Score and Modified Glasgow Prognostic Score in a Western cohort. Eur J Surg Oncol 2020;46:804-10. [PMID: 31848078 DOI: 10.1016/j.ejso.2019.12.008] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
5 Lu J, Li B, Li FY, Ye H, Xiong XZ, Cheng NS. Long-term outcome and prognostic factors of intrahepatic cholangiocarcinoma involving the hepatic hilus versus hilar cholangiocarcinoma after curative-intent resection: Should they be recognized as perihilar cholangiocarcinoma or differentiated? Eur J Surg Oncol 2019;45:2173-9. [PMID: 31208772 DOI: 10.1016/j.ejso.2019.06.014] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
6 Lauterio A, De Carlis R, Centonze L, Buscemi V, Incarbone N, Vella I, De Carlis L. Current Surgical Management of Peri-Hilar and Intra-Hepatic Cholangiocarcinoma. Cancers (Basel) 2021;13:3657. [PMID: 34359560 DOI: 10.3390/cancers13153657] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Noji T, Tanaka K, Matsui A, Nakanishi Y, Asano T, Nakamura T, Tsuchikawa T, Okamura K, Hirano S. Transhepatic Direct Approach to the "Limit of the Division of the Hepatic Ducts" Leads to a High R0 Resection Rate in Perihilar Cholangiocarcinoma. J Gastrointest Surg 2021. [PMID: 33403562 DOI: 10.1007/s11605-020-04891-1] [Reference Citation Analysis]
8 Belkouz A, Nooijen LE, Riady H, Franken LC, van Oijen MGH, Punt CJA, Erdmann JI, Klümpen HJ. Efficacy and safety of systemic induction therapy in initially unresectable locally advanced intrahepatic and perihilar cholangiocarcinoma: A systematic review. Cancer Treat Rev 2020;91:102110. [PMID: 33075684 DOI: 10.1016/j.ctrv.2020.102110] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]